{"id":5885,"date":"2021-01-05T11:13:44","date_gmt":"2021-01-05T03:13:44","guid":{"rendered":"http:\/\/simedarbyoilsnutrition.com\/?post_type=researches&p=5885"},"modified":"2021-01-05T16:18:40","modified_gmt":"2021-01-05T08:18:40","slug":"effects-of-delta-tocotrienol-supplementation-on-liver-enzymes-inflammation-oxidative-stress-and-hepatic-steatosis-in-patients-with-nonalcoholic-fatty-liver-disease-2","status":"publish","type":"researches","link":"https:\/\/sdguthrie-nutrition.com\/en\/researches\/effects-of-delta-tocotrienol-supplementation-on-liver-enzymes-inflammation-oxidative-stress-and-hepatic-steatosis-in-patients-with-nonalcoholic-fatty-liver-disease-2\/","title":{"rendered":"Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease"},"content":{"rendered":"
Abstract:<\/p>\n\n\n\n
Background: <\/strong>Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and is associated with increased morbidity and mortality. Currently, there is no definitive treatment for this disease. \u03b4-Tocotrienol has potent anti-inflammatory and antioxidant properties and may reduce liver injury in NAFLD. The present study aims to evaluate the efficacy and safety of \u03b4-tocotrienol in the treatment of NAFLD.<\/p>\n\n\n\n Materials and Methods:<\/strong> The present study was a randomized, double-blind, placebo-controlled pilot study conducted in patients aged > 20 years, belonging to both sexes, having ultrasound-proven fatty liver disease, having a fatty liver index (FLI) of \u2265 60, and persistent elevation of alanine transaminase. A total of 71 patients were assigned to receive either oral \u03b4-tocotrienol (n=35, 300 mg twice daily) or placebo (n=36) for 12 weeks. At the baseline and at the end of the study, clinical and biochemical parameters, including lipid profile, liver function tests, high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde (MDA) were measured. Body mass index and FLI were calculated, and ultrasound grading of hepatic steatosis was performed.<\/p>\n\n\n\n Results:<\/strong> Out of 71 enrolled patients, 64 patients, 31 in the \u03b4-tocotrienol group and 33 in the placebo group, completed the study. After 12 weeks of supplementation, \u03b4-tocotrienol showed greater efficacy than placebo by decreasing serum aminotransferases, hs-CRP, MDA, and FLI score (p<0.001). However, it did not improve hepatic steatosis on ultrasound examination. No adverse effects were reported.<\/p>\n\n\n\n Conclusion:<\/strong> \u03b4-Tocotrienol was safe, and it effectively improved aminotransferase levels and inflammatory and oxidative stress markers in patients with NAFLD. Large-scale randomized clinical trials are warranted to further support these findings.<\/p>","protected":false},"featured_media":13507,"template":"","access":[],"research_tags":[175],"acf":[],"yoast_head":"\n